Participated · Series D · Feb 2026

ElevenLabs builds AI voice models and provides voice-as-a-service offerings aimed at enterprise customers, including multilingual automation and in-network AI agent use cases. The company has secured enterprise contracts with customers such as Deutsche Telekom, Revolut, and Klarna. ElevenLabs reported rapid revenue growth, ending last year with nearly $350 million in ARR, adding $100 million in net new ARR in Q1 2026 to reach roughly $450 million, and later surpassing $500 million in ARR. Its valuation climbed from $6.6 billion in September to $11 billion in February. The startup recently acquired the team from Polish voice AI startup Papla to bolster its research capabilities. It has also completed a $100 million tender and is enabling retail investment via Robinhood Ventures as part of its fundraising activity.

Participated · Series F · Sep 2025

Vercel is the company behind v0, Next.js, and the AI Cloud, delivering secure, scalable infrastructure for building AI-native applications. Its platform serves a spectrum of customers from solo developers to global enterprises such as Anthropic, OpenAI, Square, PayPal, Supreme, Nike, AT&T, Hulu, Target, and Walmart. Over the past year the company has doubled its user base and recorded 82% year-over-year top-line growth. v0, Vercel’s AI development agent, has attracted more than 3.5 million unique users, with Teams and Enterprise accounts now contributing over 50% of v0 revenue, while the AI SDK logs 3 million weekly downloads. The firm is extending its offering with v0 Mobile—now in public beta and waitlisted by 10,000 users—enabling application creation via voice and camera input. Future investments will focus on scaling the AI Gateway, AI Sandbox, and AI SDK to deepen enterprise adoption. To support this growth, Vercel has added senior executives from Stripe, Redis, Capital One, HashiCorp, and IBM.

Participated · Series D · Apr 2025

Cyberhaven is an AI-powered data security company offering a data detection and response platform built on data lineage and foundational AI. The company's approach traces how data originates, moves, and transforms and uses a proprietary Large Lineage Model (LLiM) to provide real-time observability and precise threat detection. Its platform is designed to detect and stop critical risks to sensitive data across endpoints, cloud platforms, and AI systems. Cyberhaven emphasizes behavioral, AI-driven analysis of data flows rather than traditional content scanning. The company plans to expand its platform through both M&A and organic innovation and to increase go-to-market investments. Financially, the company has raised a total of $250 million to date and was valued at $1 billion after its latest round. Cyberhaven provides AI-powered data detection and response technology to detect and stop critical insider threats to sensitive information. Its platform uses data lineage technology and a foundational AI model that understands both content and context to classify sensitive information and identify when it is at risk. The company says its AI analyzes billions of workflows to map every piece of data within an organization and take action to protect it. Cyberhaven focuses on protecting intellectual property that traditional DLP, insider risk, and DSPM tools fail to secure, including source code, product designs, and customer records. Led by CEO Howard Ting and based in San Jose, California, the company intends to use new funding to expand product offerings, increase market reach, and continue its mission to protect sensitive data. Cyberhaven provides the industry's first Data Detection and Response (DDR) platform that maps the full journey of every piece of data to classify sensitive content, detect risk, and proactively enforce policy. The platform is a fully managed SaaS service that requires zero infrastructure deployment or management and collects events from endpoints and cloud apps. Cyberhaven automatically discovers and tracks sensitive content of any type and identifies risk without complex rules or tagging. Security teams can block, alert, or coach users in real time to prevent theft and misuse of intellectual property and sensitive data. The company positions itself to transform a stagnant and ineffective data protection market. Financially, the company completed a $33.0M Series B and has raised $52.0M in total funding to date. Cyberhaven delivers a Data Behavior Analytics (DaBA) platform that observes and records data behavior to provide full context on data movement across endpoints, servers and applications. The solution enables organizations to know everywhere a piece of data went, who accessed it and when, so incidents can be investigated with complete context. Its core technology is protected by four patents and is based on research that received more than $1 million in grants from DARPA and the Swiss Federal Government in 2016. The company was founded in 2016 and is led by CEO Volodymyr Kuznetsov. Cyberhaven is headquartered in Palo Alto and also maintains offices in Boston and Lausanne, Switzerland. The company intends to use new funding to expand operations and broaden its business reach. Cyberhaven is a stealth-mode cybersecurity startup based in Lausanne and Boston that offers full-coverage protection of sensitive documents against cyber attacks and insider leaks. Its solution includes connectors for Office 365, on-premise Sharepoint, and Google Apps to protect enterprise workflows without changing user workflows. The core technology was developed over seven years in university labs, has been proven in the field, and is protected by four patents. The company was founded by repeat entrepreneurs and technologists groomed at EPFL, MIT, Stanford, and UC Berkeley. Cyberhaven emphasizes simplifying enterprise security by focusing on business workflows and providing broad attack-surface coverage with a seamless user experience. It plans to use new capital to fuel R&D growth in Switzerland and expand business operations in the US.

Participated · Equity · May 2022

Redcliffe Labs operates an omnichannel diagnostics platform offering lab testing, an extensive collection network and home‑collection services. The company serves over 7 million patients across more than 220 cities via 80 labs and 2,000+ collection centers. It plans to expand into Tier II and III Indian cities, open new labs, enhance its collection network and scale home‑collection offerings. Growth has been supported by strategic acquisitions in North‑Western India and partnerships with diagnostic chains. Leadership hires include Ankur Shah as an independent director and Alka Saxena as CFO, and the company highlights NABL accreditation and Six Sigma practices. Financially, operating revenue grew 2.6x to ₹347 crore in FY23 while losses widened fivefold to ₹345.6 crore, reflecting rapid expansion investments. Redcliffe Lifetech is a Noida, India–based diagnostics company that delivers pathology and specialised testing through an omni-channel infrastructure. Its network comprises 22 labs across 14 cities, several of which are NABL accredited, supported by a fleet of 400 phlebotomists operating in 100+ cities and an offline network of 500 collection centres. The company offers more than 3,500 different pathology and specialised tests, including genetics, at affordable prices. Redcliffe plans to expand its geographic reach across India with a focus on tier 2, 3 and 4 cities, scale its platform, and increase product offerings to radiology, disease data profiling and lifestyle management. Led by founder Dheeraj Jain, the business combines online channels, home sample collection, and an extensive offline footprint to reach consumers. The company will use the new funding to execute these expansion and product plans.

Participated · Equity · Apr 2021

CeQur commercializes simple-to-use, wearable insulin-delivery devices designed to replace multiple daily injections, with CeQur Simplicity as its mealtime insulin patch offering. The company reports clinical evidence showing significantly improved A1C and time-in-range outcomes and cites studies and presentations supporting patient adherence. Adoption is expanding across primary care and endocrinology practices; the company says better than 85% of claims are covered as a pharmacy benefit with an average copay of less than $45 per month. Nearly 90% of patients reported better adherence with CeQur Simplicity versus multiple daily injections, according to cited patient-experience data. CeQur has new FDA clearances and an advancing pipeline that includes extended 7-day wear and 1-unit and 2-unit patch options. The company announced a $100 million Series E to fund commercial expansion, including growth of its field sales organization.